LivaNova (NASDAQ:LIVN) Reaches New 12-Month High – Should You Buy?

LivaNova PLC (NASDAQ:LIVN) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $69.38 and last traded at $69.3250, with a volume of 908561 shares changing hands. The stock had previously closed at $68.35.

LivaNova News Summary

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 beat — LivaNova reported Q4 revenue of $360.9M (up ~12% YoY) and adjusted EPS of $0.86, topping consensus on both top and bottom lines; management highlighted organic growth across core businesses. LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Raised FY2026 EPS guidance — management issued EPS guidance of $4.15–$4.25 versus consensus near $3.90, signaling stronger-than-expected margin and earnings leverage for the year. Revenue guidance was roughly in line with consensus (~$1.5B). LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Analyst upgrade/price-target lift — Needham raised its price target to $81 and kept a Buy rating, providing additional analyst support for the rally. Livanova (LIVN) PT Raised to $81 at Needham
• Positive Sentiment: Short interest fell materially in February (down ~16.6%), lowering potential short-squeeze risk and reducing bearish positioning. (Data released by exchanges; summary in earnings coverage.)
• Neutral Sentiment: New data partnership — LivaNova announced a data partnership with Orrum that could enhance its cardiac-care analytics and reimbursement narrative, but the commercial impact is still speculative. Could LivaNova’s (LIVN) Data Partnership With Orrum Quietly Reshape Its Cardiac Care Narrative?
• Neutral Sentiment: Earnings materials and call transcript released — slide deck and full call transcript are available for investors to review execution details and product cadence. LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Margin profile and GAAP metrics — despite adjusted EPS beats, LivaNova still shows pressure on GAAP margins (company-reported net margin metrics), which investors will watch as guidance is executed. LivaNova Q4 Earnings Snapshot

Analysts Set New Price Targets

A number of research firms recently issued reports on LIVN. Needham & Company LLC increased their target price on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday. Stifel Nicolaus set a $80.00 target price on LivaNova in a research report on Wednesday. Mizuho increased their price target on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Robert W. Baird set a $75.00 price target on LivaNova in a research note on Tuesday, December 16th. Finally, KeyCorp initiated coverage on LivaNova in a report on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.11.

LivaNova Stock Performance

The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.12. The stock has a market cap of $3.88 billion, a P/E ratio of -15.92 and a beta of 0.97. The stock has a 50-day simple moving average of $64.59 and a 200-day simple moving average of $58.90.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company had revenue of $360.86 million for the quarter, compared to the consensus estimate of $354.31 million. During the same period last year, the company posted $0.81 EPS. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Research analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current year.

Hedge Funds Weigh In On LivaNova

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. lifted its stake in shares of LivaNova by 131.7% in the 4th quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock valued at $1,025,000 after purchasing an additional 9,471 shares during the period. Invesco Ltd. lifted its stake in LivaNova by 4.5% in the fourth quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock valued at $67,135,000 after buying an additional 47,323 shares during the period. Corient Private Wealth LLC acquired a new position in LivaNova in the fourth quarter valued at approximately $604,000. Mercer Global Advisors Inc. ADV bought a new position in shares of LivaNova during the 4th quarter worth approximately $306,000. Finally, State of Tennessee Department of Treasury grew its position in shares of LivaNova by 44.9% during the 4th quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company’s stock worth $1,991,000 after buying an additional 9,396 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.